This document discusses and compares two pharmaceutical companies - FDC Ltd and Ranbaxy. It analyzes their products, strategies, core values and missions. For FDC, the document focuses on its pain relief gel Arflur-D-Gel, while for Ranbaxy it discusses its competing gel Volini. Various frameworks are used to analyze the companies, finding that Ranbaxy's Volini has higher growth, awareness and market share compared to Arflur-D-Gel. The document concludes that though both are large MNCs, Ranbaxy has implemented stronger strategies for its leading pain relief gel.

1. Business Policy & Strategy
Management
Presented By:
Rahul Pawar 012003
Philomen Prem 012010
Sanjeev Kumar 012015
Mayur Gupta 012018
Jayesh Raut 012023
Swapnil Rathore 012025
Abhishek Ayarkar 012031
Pawan Sharma 012035
Khandu Chaudhari 012040
Submitted to : VISHAL SIR9/30/2013 1

2. Companies and Products:
Arflur-D-Gel
Arflur-D-Gel
9/30/2013 2

3. Freedom of choice- Wide spectrum of Therapeutic segments to choose from.
Dedication to serve- Highest quality standards with latest technology at affordable prices.
Care for all- Always committed towards better healthcare solutions.
Vision:
Expanding Health Horizons...
9/30/2013 3

4. Core Values:
1. Synergy
2. Trust
3. Competitiveness
4. Openness
5. Integrity
6. Discipline
7. Creativity
8. Quest for excellence
9/30/2013 4

5. FDC Ltd
Arflur-D-Gel
Category - Analgesic Gel (pain killer gel)
Price- ₹46/30gm
Competitors: - Volini & Volitra Gel from Ranbaxy, Omini Gel from Cipla
9/30/2013 5

6. 9/30/2013 6
Mission:
- Achieving customer satisfaction is fundamental
to our business.
- Provide products and services of the higher
quality.
- Ensure profitable growth and enhance wealth of
shareholders.
- Manage our operation with high concern for
safety and environment.
- Be a responsible corporate citizen.
Objective:
At Ranbaxy, we make good health
affordable and accessible to the local
communities and society at large.

7. Business Level Strategies:
FDC: RANBAXY:
9/30/2013 7
Product
Differentiation
Cost
Focus:
Target
Customers
Arflur-D-Gel

8. FDC : • Ranbaxy:
9/30/2013 8CONCLUSION:

9. Comparison both the companies with its
Drugs using Porter's 5 Forces:
9/30/2013 9Conclusion:

10. Comparison both the companies with its
Drugs using Generic Value Chain:
9/30/2013 10

11. Retrenchment:
• Arflur-D-Gel
• Launched 3yrs Back
• Less Growth
• Less Awareness
• Volini-Gel
• Launched 10yrs Back
• High Growth Rate
• Everyone Knows
9/30/2013 11

12. Integration:
FDC Limited:
• With a modest beginning in 1936 -
marketing vitamins and a range of
prescription formulations - FDC set up its
first formulations manufacturing facility in
1949.
• This shows that FDC follows Backward
Integration.
9/30/2013 12
Ranbaxy:
It started as a Distributor in 1937.
In 1951, Ranbaxy started manufacturing with
Italian Company Lepitit.
It shows its backward Integration.

13. BCG Matrix
High
Low
High
Low
B
U
S
I
N
E
S
S
G
R
O
W
T
H
R
A
T
E
Market Share 13
Star
Product

14. Conclusion:
• Though Ranbaxy and F.D.C both are MNC still the
companies have there own strategies.
• As discussed all models proves that Ranbaxy stands far
better than FDC with its product Volini.
9/30/2013 14

15. 9/30/2013 15